Delcath Systems, Inc. (NASDAQ:DCTH) Shares Bought by Jane Street Group LLC

Jane Street Group LLC lifted its stake in shares of Delcath Systems, Inc. (NASDAQ:DCTH) by 1,364.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 178,797 shares of the company’s stock after acquiring an additional 166,589 shares during the period. Jane Street Group LLC owned 0.56% of Delcath Systems worth $2,153,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Barclays PLC purchased a new stake in Delcath Systems in the 3rd quarter valued at about $104,000. Baader Bank Aktiengesellschaft purchased a new stake in Delcath Systems during the fourth quarter worth approximately $204,000. Principal Financial Group Inc. increased its position in shares of Delcath Systems by 28.8% in the fourth quarter. Principal Financial Group Inc. now owns 115,183 shares of the company’s stock worth $1,387,000 after acquiring an additional 25,736 shares in the last quarter. Private Advisor Group LLC purchased a new position in Delcath Systems in the fourth quarter valued at about $153,000. Finally, Charles Schwab Investment Management Inc. acquired a new position in Delcath Systems during the 4th quarter worth approximately $156,000. Hedge funds and other institutional investors own 61.12% of the company’s stock.

Delcath Systems Stock Performance

DCTH stock opened at $17.10 on Friday. The stock has a market capitalization of $595.52 million, a price-to-earnings ratio of -12.67 and a beta of 0.72. Delcath Systems, Inc. has a 1 year low of $6.33 and a 1 year high of $17.15. The stock’s fifty day moving average is $12.61 and its two-hundred day moving average is $12.74.

Delcath Systems (NASDAQ:DCTH) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative net margin of 150.70% and a negative return on equity of 338.16%. The company had revenue of $19.80 million for the quarter, compared to the consensus estimate of $16.83 million. As a group, analysts predict that Delcath Systems, Inc. will post -0.79 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Craig Hallum increased their price objective on shares of Delcath Systems from $18.00 to $21.00 and gave the company a “buy” rating in a research report on Friday, January 17th. HC Wainwright raised their price objective on Delcath Systems from $22.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Delcath Systems has an average rating of “Moderate Buy” and an average target price of $22.75.

Delcath Systems Profile

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.